このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Novo Nordisk 過去の業績

過去基準チェック /56

Novo Nordiskは、平均年間18.5%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間減少しています。収益は、平均年間0.2% 16.7%収益成長率で成長しています。 Novo Nordiskの自己資本利益率は79.9%であり、純利益率は34.8%です。

主要情報

18.5%

収益成長率

20.0%

EPS成長率

Pharmaceuticals 業界の成長	6.0%
収益成長率	16.7%
株主資本利益率	79.9%
ネット・マージン	34.8%
次回の業績アップデート	06 Nov 2024

Recent updates

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Aug 18

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Feb 23

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Feb 16

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Jan 22

Taking Novo Nordisk To The Next Level

Jan 15

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Jan 02

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Dec 12

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Nov 24

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Oct 24

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Sep 22

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Aug 30

Novo Nordisk: Denmark's Coca-Cola

Jul 25

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Jul 11

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Jun 23

収支内訳

Novo Nordisk の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NYSE:NVO 収益、費用、利益 ( )DKK Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	258,003	89,898	63,205	36,246
31 Mar 24	244,243	89,276	62,528	32,907
31 Dec 23	232,261	83,683	61,598	31,029
30 Sep 23	214,490	75,312	58,063	29,308
30 Jun 23	201,325	67,239	56,597	26,813
31 Mar 23	188,290	61,129	53,014	24,809
31 Dec 22	176,954	55,525	50,684	23,287
30 Sep 22	167,195	52,825	48,415	21,021
30 Jun 22	157,251	50,539	45,949	19,640
31 Mar 22	149,027	49,344	43,023	18,461
31 Dec 21	140,800	47,757	41,058	17,199
30 Sep 21	134,605	46,183	39,200	16,273
30 Jun 21	129,910	44,362	38,237	15,932
31 Mar 21	126,875	42,864	37,557	15,279
31 Dec 20	126,946	42,138	36,886	15,462
30 Sep 20	127,225	41,537	36,693	14,913
30 Jun 20	126,575	41,433	36,283	14,603
31 Mar 20	126,605	40,403	36,490	14,869
31 Dec 19	122,021	38,951	35,830	14,220
30 Sep 19	119,336	38,731	35,056	14,352
30 Jun 19	116,821	37,574	34,346	14,395
31 Mar 19	114,192	38,322	33,855	14,134
31 Dec 18	111,831	38,628	33,313	14,805
30 Sep 18	110,091	38,384	32,729	14,244
30 Jun 18	108,943	39,117	32,062	13,928
31 Mar 18	110,174	38,725	31,739	14,046
31 Dec 17	111,696	38,130	32,124	14,014
30 Sep 17	113,276	38,576	31,786	14,501
30 Jun 17	114,199	38,609	32,268	14,631
31 Mar 17	113,020	38,626	32,390	14,548
31 Dec 16	111,780	37,925	32,339	14,563
30 Sep 16	111,084	37,484	32,467	13,884
30 Jun 16	110,339	36,064	32,495	13,715
31 Mar 16	109,939	34,439	32,817	13,419
31 Dec 15	107,927	34,860	32,169	13,608
30 Sep 15	103,636	33,131	30,712	13,616
30 Jun 15	99,093	31,248	29,578	13,381
31 Mar 15	93,663	29,899	27,870	13,421
31 Dec 14	88,806	26,481	26,760	13,762
30 Sep 14	85,919	26,005	26,571	12,863
30 Jun 14	84,181	25,920	26,153	12,604
31 Mar 14	83,932	25,660	26,448	12,244
31 Dec 13	83,572	25,184	26,888	11,733
30 Sep 13	82,836	24,886	26,514	11,377

質の高い収益: NVO 非現金収入のレベルが高いです。

利益率の向上: NVOの現在の純利益率 (36.6%)は、昨年(32.5%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: NVOの収益は過去 5 年間で年間17.1%増加しました。

成長の加速: NVOの過去 1 年間の収益成長率 ( 33.7% ) は、5 年間の平均 ( 年間18.5%を上回っています。

収益対業界: NVOの過去 1 年間の収益成長率 ( 33.7% ) はPharmaceuticals業界13%を上回りました。

株主資本利益率

高いROE: NVOの自己資本利益率 ( 79.9% ) は傑出していると考えられます。

Novo Nordisk 過去の業績

過去 基準チェック /56

主要情報

最近の業績更新

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Recent updates

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Novo Nordisk A/S Provides Earnings Guidance for the Year 2024

Novo Nordisk: Better Buying Opportunities Ahead

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk: Buy On Dips

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Novo Nordisk: Considerable Growth Beyond Ozempic

The FTC Cracks Down On Novo Nordisk's Ozempic

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Novo Nordisk: The Moat Won't Last Forever

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Novo Nordisk, A Very Healthy Pharma Stalwart

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Taking Novo Nordisk To The Next Level

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk: Denmark's Coca-Cola

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /56